Clinical efficacy and adverse reactions of cisp latin combined with endostar thoracic perfusion in the treatment ofmalignant p leural effusion of lung cancer
ZOU Jun-tao HU Zhen-zhen CHEN Ying-lan
Department of Thoracic Oncology,Tumor Hospital of Jiangxi Province,Nanchang 330029,China
Abstract:Objective To explore the clinical effects and adverse reactions of cisplatin combined with endostar thoracic perfusion in the treatment ofmalignant pleural effusion of lung cancer.Methods 72 patientswith malignant pleural effusion of lung cancer in our hospital from December 2014 to November 2015 were selected and randomly divided into the study group and the control group,36 cases in each group.The control group was treated with cisplatin intrapleural infusion alone,the study group was treated with cisplatin combined with endostar thoracic perfusion.After 2 cycles of treatment,the clinical effects and adverse reaction incidence rate of the two groupswas compared,and the concentration of the pleural effusion,serum VEGF after treatment for 3 days and 7 days in the two groupswas compared.Results The total effective rate in the study group was 80.6%,which was higher than 58.3%in the control group,with significant difference (P<0.05).The incidence rate of adverse reactions of the two groups was compared,and the difference was not statistically significant(P>0.05).The concentration of the pleural effusion,serum VEGF in the study group after treatment for 7 days was lower than that after treatment for 3 days and in the control group after treatment for 7 days,with significant difference(P<0.05).Conclusion The treatment effects of cisplatin combined with endostar thoracic perfusion in the treatment ofmalignant pleural effusion of lung cancer is significant,the incidence rate of adverse reaction is lower,and which can control the expression function of VEGF.
邹俊韬;胡珍珍;陈颖兰. 顺铂联合恩度胸腔灌注治疗肺癌恶性胸腔积液的临床效果和不良反应观察[J]. 中国当代医药, 2016, 23(24): 22-24.
ZOU Jun-tao;HU Zhen-zhen;CHEN Ying-lan. Clinical efficacy and adverse reactions of cisp latin combined with endostar thoracic perfusion in the treatment ofmalignant p leural effusion of lung cancer. 中国当代医药, 2016, 23(24): 22-24.